Caris Q3 Net Income Declines 37% Despite 27% Revenue Growth; Raises FY26 Outlook
Caris Life Sciences (CAI) reported Q3 2026 net income down 37% YoY to $15.3M, despite 27% revenue growth to $275.4M. Operating expenses rose 42%, and adjusted EBITDA fell. The company raised FY26 revenue guidance to $1.04B-$1.05B, citing higher clinical case volumes and improved pricing. CAI shares were up 1.13% at close but fell 11.71% in overnight trading.
How this was made
The 30-second read
Why it matters
The earnings miss triggered an 11.7% after‑hours drop, yet the raised guidance may cushion further downside.
Market read
First‑time earnings release with new guidance; material for biotech traders.
What to watch
Cash position of $767M provides runway for R&D and potential acquisitions.
Background
Caris Life Sciences reported Q3 2026 results with a profit decline but strong revenue growth and raised full‑year guidance.
Ticker impact
Q3 net income fell 37% to $15.3M while revenue rose 27% to $275.4M; company raised FY2026 revenue guidance to $1.04‑$1.05B.
likely pressure as investors weigh profit decline against revenue growth and higher guidance
The sharp drop in net income and after‑hours share decline suggest downside, but the raised revenue outlook may limit the sell‑off.
Market effects
Highlights growing demand for molecular profiling, may benefit peers in precision‑medicine space.
U.S. biotech sector could see modest volatility as investors reassess earnings quality.
Limited to biotech investors; no broad macro impact.
Counterpoint
Revenue acceleration and higher guidance could outweigh profit dip, supporting a bounce.
Key entities
- companyCaris Life Sciences, Inc.
TechBio firm focused on precision medicine and molecular profiling.


